Larimar Historical Financial Ratios

LRMR Stock

USD 2.35 0.05 2.08%

Larimar Therapeutics is lately reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Larimar Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Larimar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Larimar Stock, please use our How to Invest in Larimar Therapeutics guide.

About Larimar Financial Ratios Analysis

Larimar TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Larimar Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Larimar financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Larimar Therapeutics history.

Larimar Therapeutics Financial Ratios Chart

At this time, Larimar Therapeutics' PTB Ratio is relatively stable compared to the past year. As of 03/28/2025, Capex To Depreciation is likely to grow to 2.45, while Free Cash Flow Yield is likely to drop (0.32).

Payables Turnover Average Inventory Cash Per Share Days Payables Outstanding

Add Fundamental

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Average Inventory

The average amount of inventory a company holds over a certain period, which is used to calculate inventory turnover and efficiency in managing stock levels.

Most ratios from Larimar Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Larimar Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Larimar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Larimar Stock, please use our How to Invest in Larimar Therapeutics guide.At this time, Larimar Therapeutics' PTB Ratio is relatively stable compared to the past year. As of 03/28/2025, Capex To Depreciation is likely to grow to 2.45, while Free Cash Flow Yield is likely to drop (0.32).

	2022	2023	2024	2025 (projected)
Current Ratio	11.28	9.49	8.02	11.01
Net Debt To EBITDA	0.61	0.51	0.31	0.29

Current Ratio Net Debt To E B I T D A

Larimar Therapeutics fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield
Ptb Ratio		0.03	0.26	-0.08	0.34	1.0	-0.08	-0.91	0.02	-0.07	-0.56	-0.06	0.01	-0.01	-0.52	-0.29	0.14	-0.52	0.32	-0.06	-0.91	-0.51	-0.52	0.69	-0.51	0.23
Book Value Per Share	0.03		-0.49	-0.94	0.3	0.03	-0.94	-0.19	0.39	-0.95	0.11	-0.23	0.25	0.99	0.22	0.02	-0.39	0.22	0.2	-0.47	-0.19	0.21	0.24	0.31	0.21	-0.52
Free Cash Flow Yield	0.26	-0.49		0.51	0.17	0.26	0.52	0.02	0.05	0.51	-0.21	-0.42	0.23	-0.5	-0.82	0.25	0.74	-0.82	0.65	0.34	0.01	-0.82	-0.81	-0.21	-0.82	1.0
Operating Cash Flow Per Share	-0.08	-0.94	0.51		-0.28	-0.08	1.0	0.18	-0.49	1.0	-0.3	0.23	-0.31	-0.96	-0.17	0.16	0.29	-0.17	-0.17	0.38	0.18	-0.17	-0.19	-0.22	-0.17	0.54
Capex To Depreciation	0.34	0.3	0.17	-0.28		0.34	-0.28	-0.16	0.36	-0.29	-0.32	-0.47	0.06	0.27	-0.46	-0.4	-0.24	-0.46	0.63	-0.09	-0.16	-0.43	-0.43	-0.03	-0.43	0.15
Pb Ratio	1.0	0.03	0.26	-0.08	0.34		-0.08	-0.91	0.02	-0.07	-0.56	-0.06	0.01	-0.01	-0.52	-0.29	0.14	-0.52	0.32	-0.06	-0.91	-0.51	-0.52	0.69	-0.51	0.23
Free Cash Flow Per Share	-0.08	-0.94	0.52	1.0	-0.28	-0.08		0.18	-0.49	1.0	-0.3	0.23	-0.31	-0.96	-0.17	0.16	0.29	-0.17	-0.17	0.38	0.18	-0.17	-0.19	-0.22	-0.17	0.54
Roic	-0.91	-0.19	0.02	0.18	-0.16	-0.91	0.18		0.15	0.18	0.54	-0.19	0.08	-0.15	0.18	0.1	0.04	0.18	-0.04	0.23	1.0	0.17	0.18	-0.92	0.17	0.05
Inventory Turnover	0.02	0.39	0.05	-0.49	0.36	0.02	-0.49	0.15		-0.48	0.32	-0.35	0.29	0.42	-0.39	-0.13	0.02	-0.39	0.52	-0.15	0.15	-0.4	-0.38	-0.27	-0.4	0.03
Net Income Per Share	-0.07	-0.95	0.51	1.0	-0.29	-0.07	1.0	0.18	-0.48		-0.3	0.21	-0.3	-0.97	-0.19	0.13	0.29	-0.19	-0.17	0.43	0.18	-0.19	-0.21	-0.23	-0.19	0.54
Days Of Inventory On Hand	-0.56	0.11	-0.21	-0.3	-0.32	-0.56	-0.3	0.54	0.32	-0.3		0.09	0.18	0.21	0.31	0.12	0.3	0.31	-0.25	-0.08	0.54	0.3	0.31	-0.48	0.3	-0.22
Payables Turnover	-0.06	-0.23	-0.42	0.23	-0.47	-0.06	0.23	-0.19	-0.35	0.21	0.09		-0.45	-0.21	0.61	0.1	-0.27	0.61	-0.81	-0.25	-0.18	0.62	0.61	0.33	0.62	-0.43
Average Inventory	0.01	0.25	0.23	-0.31	0.06	0.01	-0.31	0.08	0.29	-0.3	0.18	-0.45		0.26	-0.25	-0.03	0.31	-0.25	0.33	-0.19	0.08	-0.24	-0.24	-0.15	-0.24	0.21
Cash Per Share	-0.01	0.99	-0.5	-0.96	0.27	-0.01	-0.96	-0.15	0.42	-0.97	0.21	-0.21	0.26		0.24	0.03	-0.34	0.24	0.18	-0.49	-0.15	0.23	0.27	0.27	0.23	-0.53
Pocfratio	-0.52	0.22	-0.82	-0.17	-0.46	-0.52	-0.17	0.18	-0.39	-0.19	0.31	0.61	-0.25	0.24		0.08	-0.53	1.0	-0.84	-0.34	0.19	1.0	0.99	0.1	1.0	-0.82
Interest Coverage	-0.29	0.02	0.25	0.16	-0.4	-0.29	0.16	0.1	-0.13	0.13	0.12	0.1	-0.03	0.03	0.08		0.33	0.08	-0.03	-0.07	0.1	0.07	0.1	0.16	0.07	0.24
Capex To Operating Cash Flow	0.14	-0.39	0.74	0.29	-0.24	0.14	0.29	0.04	0.02	0.29	0.3	-0.27	0.31	-0.34	-0.53	0.33		-0.53	0.32	0.26	0.04	-0.54	-0.53	-0.16	-0.54	0.73
Pfcf Ratio	-0.52	0.22	-0.82	-0.17	-0.46	-0.52	-0.17	0.18	-0.39	-0.19	0.31	0.61	-0.25	0.24	1.0	0.08	-0.53		-0.84	-0.34	0.19	1.0	0.99	0.1	1.0	-0.82
Days Payables Outstanding	0.32	0.2	0.65	-0.17	0.63	0.32	-0.17	-0.04	0.52	-0.17	-0.25	-0.81	0.33	0.18	-0.84	-0.03	0.32	-0.84		0.19	-0.04	-0.84	-0.83	-0.16	-0.84	0.63
Income Quality	-0.06	-0.47	0.34	0.38	-0.09	-0.06	0.38	0.23	-0.15	0.43	-0.08	-0.25	-0.19	-0.49	-0.34	-0.07	0.26	-0.34	0.19		0.23	-0.35	-0.42	-0.33	-0.35	0.4
Roe	-0.91	-0.19	0.01	0.18	-0.16	-0.91	0.18	1.0	0.15	0.18	0.54	-0.18	0.08	-0.15	0.19	0.1	0.04	0.19	-0.04	0.23		0.18	0.18	-0.92	0.18	0.05
Ev To Operating Cash Flow	-0.51	0.21	-0.82	-0.17	-0.43	-0.51	-0.17	0.17	-0.4	-0.19	0.3	0.62	-0.24	0.23	1.0	0.07	-0.54	1.0	-0.84	-0.35	0.18		0.99	0.11	1.0	-0.82
Pe Ratio	-0.52	0.24	-0.81	-0.19	-0.43	-0.52	-0.19	0.18	-0.38	-0.21	0.31	0.61	-0.24	0.27	0.99	0.1	-0.53	0.99	-0.83	-0.42	0.18	0.99		0.11	0.99	-0.81
Return On Tangible Assets	0.69	0.31	-0.21	-0.22	-0.03	0.69	-0.22	-0.92	-0.27	-0.23	-0.48	0.33	-0.15	0.27	0.1	0.16	-0.16	0.1	-0.16	-0.33	-0.92	0.11	0.11		0.11	-0.24
Ev To Free Cash Flow	-0.51	0.21	-0.82	-0.17	-0.43	-0.51	-0.17	0.17	-0.4	-0.19	0.3	0.62	-0.24	0.23	1.0	0.07	-0.54	1.0	-0.84	-0.35	0.18	1.0	0.99	0.11		-0.82
Earnings Yield	0.23	-0.52	1.0	0.54	0.15	0.23	0.54	0.05	0.03	0.54	-0.22	-0.43	0.21	-0.53	-0.82	0.24	0.73	-0.82	0.63	0.4	0.05	-0.82	-0.81	-0.24	-0.82

Click cells to compare fundamentals

Larimar Therapeutics Account Relationship Matchups

Larimar Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	2.84	2.88	0.96	2.44	1.38	1.45
Book Value Per Share	7.55	3.75	4.31	1.86	2.8	2.66
Free Cash Flow Yield	(0.32)	(0.19)	(0.17)	(0.23)	(0.26)	(0.3)
Operating Cash Flow Per Share	(3.55)	(2.45)	(1.07)	(0.76)	(1.16)	(1.21)
Capex To Depreciation	0.4	1.02	0.31	0.53	1.62	2.45
Pb Ratio	2.84	2.88	0.96	2.44	1.38	1.45
Roic	(0.44)	(0.71)	(0.3)	(0.48)	(0.51)	(0.49)
Net Income Per Share	(3.56)	(2.93)	(1.33)	(0.84)	(1.32)	(1.38)
Payables Turnover	0.0588	0.2	0.16	0.24	0.22	0.23
Cash Per Share	7.8	4.08	4.6	1.98	2.99	2.85
Pocfratio	(6.03)	(4.4)	(3.86)	(5.97)	(3.35)	(3.52)
Capex To Operating Cash Flow	(0.001469)	(0.007909)	(0.003627)	(0.004902)	(0.007278)	(0.007642)
Pfcf Ratio	(6.02)	(4.36)	(3.85)	(5.94)	(3.33)	(3.49)
Days Payables Outstanding	6.2K	1.9K	2.3K	1.5K	1.7K	1.6K
Roe	(0.66)	33.33	(0.47)	(0.78)	(0.31)	(0.45)
Ev To Operating Cash Flow	(4.57)	(2.88)	(3.08)	(5.34)	(2.95)	(3.1)
Pe Ratio	(6.01)	(3.68)	(3.11)	(5.41)	(2.94)	(3.09)
Return On Tangible Assets	(0.5)	(4.45)	(0.4)	(0.64)	(0.27)	(0.42)
Ev To Free Cash Flow	(4.56)	(2.85)	(3.07)	(5.31)	(2.93)	(3.08)
Earnings Yield	(0.17)	(0.27)	(0.32)	(0.18)	(0.34)	(0.36)
Net Debt To E B I T D A	1.45	1.28	0.61	0.51	0.31	0.29
Current Ratio	10.89	8.16	11.28	9.49	8.02	11.01
Tangible Book Value Per Share	7.55	3.75	4.31	1.86	2.8	2.66
Shareholders Equity Per Share	7.55	3.75	4.31	1.86	2.8	2.66
Debt To Equity	0.0727	0.0932	0.0488	0.0679	0.0298	0.0283
Capex Per Share	0.005217	0.0194	0.003882	0.003736	0.008407	0.007987
Graham Net Net	6.53	3.26	4.0	1.65	2.53	2.4
Interest Debt Per Share	0.55	0.35	0.21	0.13	0.0835	0.0794
Debt To Assets	0.0623	0.0763	0.0428	0.0578	0.0256	0.0243
Enterprise Value Over E B I T D A	(5.27)	(4.52)	(2.42)	(4.31)	(2.3)	(2.41)
Price Earnings Ratio	(6.01)	(3.68)	(3.11)	(5.41)	(2.94)	(3.09)
Price Book Value Ratio	2.84	2.88	0.96	2.44	1.38	1.45
Price Earnings To Growth Ratio	(0.14)	0.21	0.057	0.15	(0.0515)	(0.054)

Pair Trading with Larimar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Larimar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Larimar Stock

0.83	CDIOW	Cardio Diagnostics	Pair Corr
0.67	ELVN	Enliven Therapeutics	Pair Corr

Moving against Larimar Stock

0.82	LUCD	Lucid Diagnostics	Pair Corr
0.75	WM	Waste Management	Pair Corr
0.61	GE	GE Aerospace	Pair Corr
0.43	PLX	Protalix Biotherapeutics	Pair Corr
0.34	PG	Procter Gamble	Pair Corr

The ability to find closely correlated positions to Larimar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Larimar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Larimar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Larimar Therapeutics to buy it.

The correlation of Larimar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Larimar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Larimar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Larimar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Larimar Stock Analysis

When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Larimar Historical Financial Ratios

About Larimar Financial Ratios Analysis

Larimar Therapeutics Financial Ratios Chart

Payables Turnover

Average Inventory

Larimar Therapeutics fundamentals Correlations

Larimar Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Larimar Therapeutics fundamentals Accounts

Pair Trading with Larimar Therapeutics

Moving together with Larimar Stock

Moving against Larimar Stock

Additional Tools for Larimar Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Earnings Yield	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Free Cash Flow Per Share
Roe	+ 1.0	Roic

Cash Per Share	- 0.97	Net Income Per Share
Cash Per Share	- 0.96	Free Cash Flow Per Share
Cash Per Share	- 0.96	Operating Cash Flow Per Share
Net Income Per Share	- 0.95	Book Value Per Share
Free Cash Flow Per Share	- 0.94	Book Value Per Share
Operating Cash Flow Per Share	- 0.94	Book Value Per Share